Taselisib

Taselisib is a pharmaceutical drug that acts as a PI3K inhibitor. It is primarily being investigated for its potential use in the treatment of various types of cancer.

Mechanism of Action

Taselisib works by inhibiting the activity of the phosphoinositide 3-kinase (PI3K) enzyme, which plays a crucial role in the PI3K/AKT/mTOR pathway. This pathway is involved in cell growth, proliferation, and survival. By inhibiting PI3K, taselisib can potentially reduce the growth and spread of cancer cells.

Clinical Trials

Taselisib has been evaluated in several clinical trials to determine its efficacy and safety in treating different types of cancer, including breast cancer, lung cancer, and colorectal cancer. These trials have provided valuable insights into the drug's potential benefits and side effects.

Side Effects

Common side effects of taselisib include diarrhea, hyperglycemia, rash, and fatigue. More severe side effects can include pneumonitis and colitis. Patients undergoing treatment with taselisib are closely monitored for these adverse effects.

Development and Approval

Taselisib is being developed by Genentech, a subsidiary of Roche. As of the latest updates, taselisib has not yet received approval from major regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

See Also

• PI3K inhibitors
• Cancer treatment
• Pharmacology
• Clinical trials

External Links

-

   This article is a medical stub. You can help WikiMD by expanding it!